ERBB2 and breast carcinoma: In addition, HER2-targeted therapies have been used as neoadjuvant systemic therapy (i.e., regimen started before surgery) with the aim of improving operability and the pathological complete response (pCR) in early-stage or locally advanced breast cancers [3,4,5].